Traumeel S – bioregulatory approach in the treatment of inflammation

Abstract

Background: In the treatment of inflammation, the action of widely used non-steroidal anti-inflammatory drugs (NSAIDs) is directed mainly to inhibit the synthesis of proinflammatory mediators, cell migration and proliferation, as well as to stimulate the formation of anti-inflammatory agents. These effects allow to quickly and significantly limit the severe symptoms of acute inflammation and pain. However, at the same time, NSAIDs suppress the sanogenetic mechanism of inflammation. Absence of correction of pathogenetic mechanisms of inflammation can lead to chronic inflammation and development of its complications (cicatricial changes, adhesions, contractures, etc.). Also, nonselectivity of NSAIDs contributes to the development of known side effects. And inhibitors of cyclooxygenase 2, as it became known, with excess daily therapeutic dose also cause serious side effects. New possibilities for solving this problem have already been demonstrated by the bioregulatory approach and the complex bioregulatory medicines (BRMs) created on its principles. Conclusions: The complex bioregulatory action of the medicine Traumeel S allows to control and optimize the course of the inflammatory process wherever it is located and of any form. Its use contributes to the full completion of inflammation with the recovery of the structure and function of the tissue, reduces the risk of complications and chronic inflammation. Such characteristics, combined with good tolerability (absence of side effects characteristic to NSAIDs) make Traumeel S a simple and reliable assistant to a doctor of any specialty in the treatment of inflammatory diseases of different localization.

Keywords

• Traumeel S
• bioregulatory approach
• inflammation